RB1 and hepatocellular carcinoma: Sorafenib can also suppress several critical cell-cycle regulators, including cyclin D, CDKs, and E2F1-Rb-cyclin E1 complex, which plays crucial roles in mediating sorafenib resistance in HCC [44].